Alkem Laboratories Sees Sharp Open Interest Surge Amid Rising Market Activity

Open Interest and Volume Dynamics

The latest data reveals that Alkem Laboratories’ open interest (OI) rose sharply from 11,947 to 13,849 contracts, an increase of 1,902 contracts or 15.92% on a single trading day. This rise in OI was accompanied by a futures volume of 6,479 contracts, indicating robust trading activity. The combined futures and options value stood at approximately ₹1,91,67.65 lakhs, with futures contributing ₹18,622.29 lakhs and options an overwhelming ₹2,74,79,74,477 lakhs in notional value terms. The underlying stock price closed at ₹5,565, having touched an intraday high of ₹5,631, up 2.37% on the day.

Such a pronounced increase in open interest alongside rising volume typically suggests fresh capital entering the market, either through new long positions or short sellers adding to their exposure. Given the stock’s recent price appreciation and technical positioning above all major moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), the data points towards a bullish bias among derivatives traders.

Market Positioning and Directional Bets

Alkem Laboratories has been under the scanner for its evolving market sentiment. The stock has reversed its recent two-day decline, gaining 1.44% on the day, though it slightly underperformed its sector by 0.35%. The delivery volume on 2 July rose by 4.33% to 1.64 lakh shares compared to the five-day average, signalling increased investor participation in the cash segment as well. This rising delivery volume, coupled with the surge in derivatives open interest, suggests that investors are not only trading on short-term momentum but also accumulating shares for longer-term exposure.

From a technical standpoint, the stock’s trading above all key moving averages indicates a strong uptrend, which often attracts momentum traders and institutional investors. The liquidity profile supports sizeable trades, with the stock’s average traded value allowing for trade sizes up to ₹2.87 crore without significant market impact. This liquidity is crucial for derivatives traders who require efficient entry and exit points.

Mojo Score and Rating Upgrade

Alkem Laboratories currently holds a Mojo Score of 54.0, which places it in the ‘Hold’ category, an upgrade from its previous ‘Sell’ rating as of 30 June 2026. This improvement reflects a better outlook on the company’s fundamentals and technical positioning. The mid-cap pharmaceutical player, with a market capitalisation of ₹66,401 crore, is showing signs of stabilising after a period of volatility, supported by steady investor interest and improving market metrics.

Sector and Benchmark Comparison

While Alkem Laboratories gained 1.26% on the day, the Pharmaceuticals & Biotechnology sector outperformed with a 1.67% rise, and the broader Sensex advanced by 0.72%. This relative underperformance, despite positive price action, may indicate cautious optimism among investors, possibly awaiting further confirmation of earnings or sectoral catalysts. Nonetheless, the stock’s ability to maintain gains above key moving averages and the surge in derivatives activity suggest that market participants are positioning for a potential upward breakout.

Implications for Investors and Traders

The sharp increase in open interest combined with rising volume and delivery participation points to a growing conviction in Alkem Laboratories’ near-term prospects. Derivatives traders appear to be taking directional bets, likely favouring long positions given the technical backdrop and recent price recovery. However, the modest underperformance relative to the sector advises a measured approach, as broader sector dynamics and macroeconomic factors could influence the stock’s trajectory.

Investors should monitor the evolution of open interest in coming sessions to gauge whether the surge represents sustained accumulation or short-term speculative interest. Additionally, tracking changes in put-call ratios and strike-wise open interest could provide deeper insights into market sentiment and potential price targets.

Conclusion: A Watchful Optimism

Alkem Laboratories’ recent surge in open interest and volume in the derivatives market underscores a renewed investor focus on the stock amid a positive technical setup. The upgrade in Mojo Grade to ‘Hold’ from ‘Sell’ further supports a cautiously optimistic outlook. While the stock has not yet outperformed its sector, the increased participation and liquidity provide a fertile ground for potential upside moves.

Market participants should continue to analyse evolving open interest patterns and price action to confirm the sustainability of this momentum. Given the pharmaceutical sector’s sensitivity to regulatory and macroeconomic developments, a balanced approach combining technical signals with fundamental analysis remains prudent.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →